Granules India’s Board of Directors has approved the unaudited financial results for Q3 2026, marking a period ending December 31, 2025. The company reported a total revenue of ₹9,073.97 million and a profit after tax of ₹1,115.82 million. The results reflect the impact of strategic decisions and market dynamics on the pharmaceutical company’s performance.
Financial Performance Overview
The company’s financial results indicate a solid performance in the third quarter. Key highlights include:
- Total Revenue: Reached ₹9,073.97 million.
- Profit After Tax: Stood at ₹1,115.82 million.
Nine-Month Performance
For the nine months ending December 31, 2025, Granules India reported:
- Total Revenue: ₹26,302.55 million.
- Profit After Tax: ₹3,016.80 million.
Key Business Developments
Several strategic activities and challenges influenced the results, which included acquisition-related costs and operational adjustments. These strategic decisions are expected to contribute positively to the company’s long-term growth.
USFDA Impact and Remediation
The Gagillapur facility received a warning letter from the US Food and Drug Administration (USFDA) in February 2025. Subsequently, the company voluntarily paused manufacturing to implement corrective actions, impacting revenue and expenses. The company has engaged consultants to enhance existing procedures and ensure thorough investigation and implementation of corrective and preventive actions.
Capital Raising Initiatives
The Board approved capital raising measures which include:
- Issuance of up to 25,000,000 convertible warrants for ₹585 per warrant.
- Issuance of up to 5,128,205 equity shares for ₹585 per share.
Source: BSE
